Reticine Pharmaids Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 24-12-2024
- Paid Up Capital ₹ 0.50 M
as on 24-12-2024
- Company Age 19 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.16 M
as on 24-12-2024
About Reticine Pharmaids
The Corporate was formerly known as Navdeep Bioceuticals Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.16 M.
Shivam Gupta, Ayush Gupta, and Yogesh Gupta serve as directors at the Company.
- CIN/LLPIN
U00304CH2005PLC029266
- Company No.
029266
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
30 Nov 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Reticine Pharmaids Limited offer?
Reticine Pharmaids Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Gastrointestinal Drugs, Common Disease Medicines, Antihistamines, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Antacid Drugs, Antibiotic Injection, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules.
Who are the key members and board of directors at Reticine Pharmaids?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivam Gupta  | Director | 27-Jul-2018 | Current |
| Ayush Gupta | Director | 21-Nov-2018 | Current |
| Yogesh Gupta | Director | 27-Jul-2018 | Current |
Financial Performance of Reticine Pharmaids.
Reticine Pharmaids Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Reticine Pharmaids?
In 2017, Reticine Pharmaids had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Bufco Vet Private LimitedActive 2 years 8 monthsShivam Gupta, Ayush Gupta and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 30 Oct 2023 | ₹2.16 M | Open |
How Many Employees Work at Reticine Pharmaids?
Unlock and access historical data on people associated with Reticine Pharmaids, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Reticine Pharmaids, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Reticine Pharmaids's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
